Patents by Inventor Heinrich Haas
Heinrich Haas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210161818Abstract: The present disclosure relates to methods for preparing RNA lipoplex particles for delivery of RNA to target tissues after parenteral administration, in particular after intravenous administration, and compositions comprising such RNA lipoplex particles. The present disclosure also relates to methods which allow preparing RNA lipoplex particles in an industrial GMP-compliant manner. Furthermore, the present disclosure relates to methods and compositions for storing RNA lipoplex particles without substantial loss of the product quality and, in particular, without substantial loss of RNA activity.Type: ApplicationFiled: February 8, 2021Publication date: June 3, 2021Inventors: Heinrich Haas, Sebastian Hörner, Isaac Hernan Esparza Borquez, Thomas Michael Hiller, Ferdia Bates
-
Publication number: 20210023100Abstract: The present invention relates to compositions comprising polyplex formulations for delivery of RNA to a target organ or a target cell after parenteral administration, in particular after intramuscular administration. More precisely, the present invention relates to formulations for administration of RNA such as self-replicating RNA, in particular by intramuscular injection. In more detail, the formulations comprise polyplex particles from single stranded RNA and a polyalkyleneimine.Type: ApplicationFiled: January 10, 2019Publication date: January 28, 2021Inventors: Ugur Sahin, Heinrich Haas, Annette Vogel, Stephanie Erbar, Kerstin Walzer, Anne Schlegel, Sebastian Hörner, Jorge Herrero Moreno, Thorsten Klamp, Sebastian Kreiter, Mustafa Diken
-
Publication number: 20200246267Abstract: The present disclosure relates to methods for preparing RNA lipoplex particles for delivery of RNA to target tissues after parenteral administration, in particular after intravenous administration, and compositions comprising such RNA lipoplex particles. The present disclosure also relates to methods which allow preparing RNA lipoplex particles in an industrial GMP-compliant manner. Furthermore, the present disclosure relates to methods and compositions for storing RNA lipoplex particles without substantial loss of the product quality and, in particular, without substantial loss of RNA activity.Type: ApplicationFiled: October 18, 2018Publication date: August 6, 2020Inventors: Heinrich Haas, Sebastian Hörner, Isaac Hernan Esparza Borquez, Thomas Michael Hiller, Ferdia Bates
-
Publication number: 20200155671Abstract: The present invention relates to RNA decorated particles such as RNA decorated lipid particles, preferably to RNA decorated liposomes. Further, the present invention relates to a pharmaceutical composition comprising RNA decorated particles such as RNA decorated lipid particles, preferably RNA decorated liposomes. Said pharmaceutical composition is useful for inducing an immune response. It is also useful in a prophylactic and/or therapeutic treatment of a disease involving an antigen. Furthermore, the present invention relates to a method for producing the RNA decorated particles such as RNA decorated lipid particles, preferably RNA decorated liposomes.Type: ApplicationFiled: January 22, 2020Publication date: May 21, 2020Inventors: Ugur Sahin, Heinrich Haas, Sebastian Kreiter, Yves Hüsemann, Mustafa Diken, Kerstin Reuter, Hossam Hefresha
-
Publication number: 20200085974Abstract: The present invention is in the field of immunotherapy, in particular tumor immunotherapy. The present invention provides pharmaceutical formulations for delivering RNA to antigen presenting cells such as dendrite cells (DCs) in the spleen after systemic administration. In particular, the formulations described herein enable to induce an immune response after systemic administration of antigen-coding RNA.Type: ApplicationFiled: September 23, 2019Publication date: March 19, 2020Applicants: BioNTech RNA Pharmaceuticals GmbH, TRON-Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg-Universitat Mainz gGInventors: Ugur Sahin, Heinrich Haas, Sebastian Kreiter, Mustafa Diken, Daniel Fritz, Martin Meng, Lena Mareen Kranz, Kerstin Reuter
-
Patent number: 10576146Abstract: The present invention relates to RNA decorated particles such as RNA decorated lipid particles, preferably to RNA decorated liposomes. Further, the present invention relates to a pharmaceutical composition comprising RNA decorated particles such as RNA decorated lipid particles, preferably RNA decorated liposomes. Said pharmaceutical composition is useful for inducing an immune response. It is also useful in a prophylactic and/or therapeutic treatment of a disease involving an antigen. Furthermore, the present invention relates to a method for producing the RNA decorated particles such as RNA decorated lipid particles, preferably RNA decorated liposomes.Type: GrantFiled: March 15, 2018Date of Patent: March 3, 2020Assignees: BIONTECH RNA PHARMACEUTICALS GMBH, TRON-TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZInventors: Ugur Sahin, Heinrich Haas, Sebastian Kreiter, Yves Hüsemann, Mustafa Diken, Kerstin Reuter, Hossam Hefesha
-
Patent number: 10485884Abstract: The present invention is in the field of immunotherapy, in particular tumor immunotherapy. The present invention provides pharmaceutical formulations for delivering RNA to antigen presenting cells such as dendrite cells (DCs) in the spleen after systemic administration. In particular, the formulations described herein enable to induce an immune response after systemic administration of antigen-coding RNA.Type: GrantFiled: March 25, 2013Date of Patent: November 26, 2019Inventors: Ugur Sahin, Heinrich Haas, Sebastian Kreiter, Mustafa Diken, Daniel Fritz, Martin Meng, Lena Mareen Kranz, Kerstin Reuter
-
Publication number: 20190321458Abstract: The present invention relates to compositions comprising polyplex formulations for delivery of RNA to a target organ or a target cell after parenteral administration, in particular after intramuscular administration. More precisely, the present invention relates to formulations for administration of RNA such as self-replicating RNA, in particular by intramuscular injection. In more detail, the formulations comprise polyplex particles from single stranded RNA and a polyalkyleneimine. The RNA may encode a protein of interest, such as a pharmaceutically active protein. Furthermore, the present invention relates to pharmaceutical products, comprising said RNA polyplex formulations for parenteral application to humans or to animals. The present invention relates as well to manufacturing of such pharmaceutical products, comprising, optionally, steps of sterile filtration, freezing and dehydration.Type: ApplicationFiled: July 14, 2017Publication date: October 24, 2019Inventors: Ugur Sahin, Heinrich Haas, Annette Vogel, Daniel Zucker, Stephanie Erbar, Kerstin Reuter, Anne Schlegel, Sebastian Hörner, Sebastian Kreiter, Mustafa Diken, Jorge Moreno Herrero
-
Patent number: 10413511Abstract: The present invention relates to the preparation of liposomes with enhanced loading capacity for pharmaceutically and/or diagnostically active agents and/or cosmetic agents which are substantially solubilized by the liposomal membranes, to liposome dispersions with enhanced stability with respect to release of the active agent and/or cosmetic agent from the liposomes obtainable by the process, and to pharmaceutical or cosmetic compositions comprising said stabilized liposome dispersions. The preparation may involve dehydration and rehydration steps of liposome dispersions which may be carried out by spray drying.Type: GrantFiled: May 20, 2011Date of Patent: September 17, 2019Assignee: SynCore Biotechnology Co., Ltd.Inventors: Heinrich Haas, Ursula Fattler
-
Publication number: 20180264106Abstract: The present invention relates to RNA decorated particles such as RNA decorated lipid particles, preferably to RNA decorated liposomes. Further, the present invention relates to a pharmaceutical composition comprising RNA decorated particles such as RNA decorated lipid particles, preferably RNA decorated liposomes. Said pharmaceutical composition is useful for inducing an immune response. It is also useful in a prophylactic and/or therapeutic treatment of a disease involving an antigen. Furthermore, the present invention relates to a method for producing the RNA decorated particles such as RNA decorated lipid particles, preferably RNA decorated liposomes.Type: ApplicationFiled: March 15, 2018Publication date: September 20, 2018Inventors: Ugur Sahin, Heinrich Haas, Sebastian Kreiter, Yves Hüsemann, Mustafa Diken, Kerstin Reuter, Hossam Hefresha
-
Publication number: 20180263907Abstract: The present invention relates to lipid particles comprising at least one cationic lipid, at least one water-soluble therapeutically effective compound and RNA. Further, the present invention relates to a pharmaceutical composition comprising such particles. Said pharmaceutical composition is useful for inducing an immune response. It is also useful in a prophylactic and/or therapeutic treatment of a disease involving an antigen. Furthermore, the present invention relates to a method for producing the particles.Type: ApplicationFiled: March 30, 2016Publication date: September 20, 2018Inventors: Hossam Hefesha, Ugur Sahin, Heinrich Haas, Sebastian Kreiter, Yves Hüsemann, Mustafa Diken, Kerstin Reuter
-
Patent number: 9950065Abstract: The present invention relates to RNA decorated particles such as RNA decorated lipid particles, preferably to RNA decorated liposomes. Further, the present invention relates to a pharmaceutical composition comprising RNA decorated particles such as RNA decorated lipid particles, preferably RNA decorated liposomes. Said pharmaceutical composition is useful for inducing an immune response. It is also useful in a prophylactic and/or therapeutic treatment of a disease involving an antigen. Furthermore, the present invention relates to a method for producing the RNA decorated particles such as RNA decorated lipid particles, preferably RNA decorated liposomes.Type: GrantFiled: September 26, 2013Date of Patent: April 24, 2018Assignees: BIONTECH RNA PHARMACEUTICALS GMBH, TRON—TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ GEMEINNUZIGE GMBHInventors: Ugur Sahin, Heinrich Haas, Sebastian Kreiter, Yves Hüsemann, Mustafa Diken, Kerstin Reuter, Hossam Hefresha
-
Publication number: 20170273907Abstract: The present invention related to aqueous lipid and/or liposome formulations with an increased chemical stability, to methods of preparing such aqueous formulations as well as to kits comprising them. The present invention further relates to methods of preparing lipid-based pharmaceutical compositions, to pharmaceutical compositions prepared by such methods and to methods of chemically stabilizing aqueous lipid and/or liposome formulations.Type: ApplicationFiled: September 17, 2015Publication date: September 28, 2017Applicant: BioNTech RNA Pharmaceuticals GmbHInventors: Heinrich HAAS, Isaac Hernan ESPARZA BORQUEZ
-
Publication number: 20160250323Abstract: The present invention relates to RNA decorated particles such as RNA decorated lipid particles, preferably to RNA decorated liposomes. Further, the present invention relates to a pharmaceutical composition comprising RNA decorated particles such as RNA decorated lipid particles, preferably RNA decorated liposomes. Said pharmaceutical composition is useful for inducing an immune response. It is also useful in a prophylactic and/or therapeutic treatment of a disease involving an antigen. Furthermore, the present invention relates to a method for producing the RNA decorated particles such as RNA decorated lipid particles, preferably RNA decorated liposomes.Type: ApplicationFiled: September 26, 2013Publication date: September 1, 2016Inventors: Ugur Sahin, Heinrich Haas, Sebastian Kreiter, Yves Hüsemann, Mustafa Diken, Kerstin Reuter, Hossam Hefesha
-
Patent number: 9238021Abstract: A method for producing a cationic liposomal preparation comprising a lipophilic active compound with physical and chemical stability during manufacturing, storing and reconstituting, and further a cationic liposomal preparation obtainable by this method as well as specific cationic liposomal preparations as well as pharmaceutical compositions are disclosed.Type: GrantFiled: January 24, 2014Date of Patent: January 19, 2016Assignee: Medigene AGInventors: Carsten Mundus, Christian Welz, Oliver Schramel, Heinrich Haas, Thomas Fichert, Brita Schulze, Toralf Peymann, Uwe Michaelis, Michael Teifel, Friedrich Gruber, Gerhard Winter
-
Publication number: 20150086612Abstract: The present invention is in the field of immunotherapy, in particular tumor immunotherapy. The present invention provides pharmaceutical formulations for delivering RNA to antigen presenting cells such as dendrite cells (DCs) in the spleen after systemic administration. In particular, the formulations described herein enable to induce an immune response after systemic administration of antigen-coding RNA.Type: ApplicationFiled: March 25, 2013Publication date: March 26, 2015Applicant: BIONTECH AGInventors: Ugur Sahin, Heinrich Haas, Sebastian Kreiter, Mustafa Diken, Daniel Fritz, Martin Meng, Lena Mareen Kranz, Kerstin Reuter
-
Publication number: 20140205657Abstract: A method for producing a cationic liposomal preparation comprising a lipophilic active compound with physical and chemical stability during manufacturing, storing and reconstituting, and further a cationic liposomal preparation obtainable by this method as well as specific cationic liposomal preparations as well as pharmaceutical compositions are disclosed.Type: ApplicationFiled: January 24, 2014Publication date: July 24, 2014Applicant: MEDIGENE AGInventors: Carsten MUNDUS, Christian WELZ, Oliver SCHRAMEL, Heinrich HAAS, Thomas FICHERT, Brita SCHULZE, Toralf PEYMANN, Uwe MICHAELIS, Michael TEIFEL, Friedrich GRUBER, Gerhard WINTER
-
Patent number: 8663606Abstract: A method for producing a cationic liposomal preparation comprising a lipophilic active compound with physical and chemical stability during manufacturing, storing and reconstituting, and further a cationic liposomal preparation obtainable by this method as well as specific cationic liposomal preparations as well as pharmaceutical compositions are disclosed.Type: GrantFiled: October 21, 2011Date of Patent: March 4, 2014Assignee: Medigene AGInventors: Carsten Mundus, Christian Welz, Oliver Schramel, Heinrich Haas, Thomas Fichert, Brita Schulze, Toralf Peymann, Uwe Michaelis, Michael Teifel, Friedrich Gruber, Gerhard Winter
-
Publication number: 20130259922Abstract: The present invention relates to the preparation of liposomes with enhanced loading capacity for pharmaceutically and/or diagnostically active agents and/or cosmetic agents which are substantially solubilized by the liposomal membranes, to liposome dispersions with enhanced stability with respect to release of the active agent and/or cosmetic agent from the liposomes obtainable by the process, and to pharmaceutical or cosmetic compositions comprising said stabilized liposome dispersions. The preparation may involve dehydration and rehydration steps of liposome dispersions which may be carried out by spray drying.Type: ApplicationFiled: May 20, 2011Publication date: October 3, 2013Applicant: MEDIGENE AGInventors: Heinrich Haas, Ursula Fattler
-
Publication number: 20120100067Abstract: The present invention relates to the solubilisation of an active agent in a lipid dispersion, in particular to the solubilisation of an active agent in a suspension of preformed empty liposomes.Type: ApplicationFiled: April 3, 2009Publication date: April 26, 2012Applicant: MEDIGENE AGInventors: Ursula Fattler, Heinrich Haas